These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1213 related articles for article (PubMed ID: 32192306)

  • 41. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
    Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
    Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.
    Zhu J; Liu F; Gu W; Lian P; Sheng W; Xu J; Cai G; Shi D; Cai S; Zhang Z
    Radiat Oncol; 2014 Mar; 9():70. PubMed ID: 24606870
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MRI-defined high-risk rectal cancer patients: outcome comparison between neoadjuvant chemoradiotherapy plus TME and TME plus adjuvant chemotherapy or TME alone.
    Jia X; Xie P; Bi L; Meng X; Wang Z; Hong N; Wang Y
    Br J Radiol; 2021 Apr; 94(1120):20201221. PubMed ID: 33591799
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Robotic versus laparoscopic sphincter-saving total mesorectal excision for mid or low rectal cancer in male patients after neoadjuvant chemoradiation therapy: comparison of long-term outcomes.
    Asoglu O; Tokmak H; Bakir B; Aliyev V; Saglam S; Iscan Y; Bademler S; Meric S
    J Robot Surg; 2020 Jun; 14(3):393-399. PubMed ID: 31313071
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction treatment with FOLFIRINOX or oxaliplatin-based doublet followed by long-course chemoradiotherapy and surgery in locally advanced rectal cancer. A systematic review and pooled analysis from phase II and III trials.
    Moretto R; Vetere G; Carullo M; Ciracì P; Masi G; Cremolini C
    Cancer Treat Rev; 2024 Nov; 130():102829. PubMed ID: 39305700
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Wait and see approach for rectal cancer with a clinically complete response after neoadjuvant concurrent chemoradiotherapy.
    Kim HJ; Song JH; Ahn HS; Choi BH; Jeong H; Choi HS; Lee YH; Kang KM; Jeong BK
    Int J Colorectal Dis; 2017 May; 32(5):723-727. PubMed ID: 27885479
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial.
    Huang CY; Bai MH; Shen JW; Sun QQ; Feng YR; Chen QP; Mao W; Ju HX; Zhu J
    BMC Cancer; 2024 Jan; 24(1):57. PubMed ID: 38200410
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Rational evaluation of the complete response after neoadjuvant therapy in locally advanced mid-low rectal cancer: the pros and cons of "watch and wait" strategy].
    Gu J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):507-513. PubMed ID: 31238630
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcomes after the watch-and-wait strategy and local excision treatment for rectal cancer: a meta-analysis.
    Li J; Ma Y; Wen L; Zhang G; Yao X
    Expert Rev Anticancer Ther; 2023 May; 23(5):555-564. PubMed ID: 36795784
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.
    Renehan AG; Malcomson L; Emsley R; Gollins S; Maw A; Myint AS; Rooney PS; Susnerwala S; Blower A; Saunders MP; Wilson MS; Scott N; O'Dwyer ST
    Lancet Oncol; 2016 Feb; 17(2):174-183. PubMed ID: 26705854
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Total mesorectal excision with or without preoperative chemoradiotherapy for resectable mid/low rectal cancer: a long-term analysis of a prospective, single-center, randomized trial.
    Wang F; Fan W; Peng J; Lu Z; Pan Z; Li L; Gao Y; Li H; Chen G; Wu X; Ding P; Zeng Z; Wan D
    Cancer Commun (Lond); 2018 Dec; 38(1):73. PubMed ID: 30572939
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
    Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
    Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intentional Watch and Wait or Organ Preservation Surgery Following Neoadjuvant Chemoradiotherapy Plus Consolidation CAPEOX for MRI-defined Low-risk Rectal Cancer: Findings From a Prospective Phase 2 Trial (PKUCH-R01 Trial, NCT02860234).
    Wang L; Zhang XY; Zhao YM; Li SJ; Li ZW; Sun YS; Wang WH; Wu AW;
    Ann Surg; 2023 Apr; 277(4):647-654. PubMed ID: 35766394
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome.
    Swellengrebel HA; Bosch SL; Cats A; Vincent AD; Dewit LG; Verwaal VJ; Nagtegaal ID; Marijnen CA
    Radiother Oncol; 2014 Jul; 112(1):44-51. PubMed ID: 25018000
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial.
    Mei WJ; Wang XZ; Li YF; Sun YM; Yang CK; Lin JZ; Wu ZG; Zhang R; Wang W; Li Y; Zhuang YZ; Lei J; Wan XB; Ren YK; Cheng Y; Li WL; Wang ZQ; Xu DB; Mo XW; Ju HX; Ye SW; Zhao JL; Zhang H; Gao YH; Zeng ZF; Xiao WW; Zhang XP; Zhang X; Xie E; Feng YF; Tang JH; Wu XJ; Chen G; Li LR; Lu ZH; Wan DS; Bei JX; Pan ZZ; Ding PR
    Ann Surg; 2023 Apr; 277(4):557-564. PubMed ID: 36538627
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is neoadjuvant chemoradiation with dose-escalation and consolidation chemotherapy sufficient to increase surgery-free and distant metastases-free survival in baseline cT3 rectal cancer?
    São Julião GP; Habr-Gama A; Vailati BB; Aguilar PB; Sabbaga J; Araújo SEA; Mattacheo A; Alexandre FA; Fernandez LM; Gomes DB; Gama-Rodrigues J; Perez RO
    Eur J Surg Oncol; 2018 Jan; 44(1):93-99. PubMed ID: 29217398
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer.
    Chen JN; Liu Z; Wang ZJ; Mei SW; Shen HY; Li J; Pei W; Wang Z; Wang XS; Yu J; Liu Q
    World J Gastroenterol; 2020 Jun; 26(21):2877-2888. PubMed ID: 32550762
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis.
    Ye W; Shi L; Qian L; Sun Y; Sun X
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1188. PubMed ID: 32721108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.